Categories: News

Federal Report Urges States To Prepare For Psychedelic FDA Approval

SAMHSA Publishes State Guidance

The Substance Abuse and Mental Health Services Administration (SAMHSA) published a new report on Wednesday regarding recent advances in psychedelic medicine. The document provides recommendations for state policymakers on how to prepare for the formal approval of drugs like psilocybin and MDMA. It also notes how the Schedule I status of many psychedelics has hampered scientific studies on their effects for decades.

“Psychedelic-assisted therapy is moving from research settings toward clinical practice faster than most observers anticipated even 5 years ago,” the report published on Wednesday by the Substance Abuse and Mental Health Services Administration (SAMHSA) says.

Research Advances and Limitations

The SAMHSA report notes that President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics in April with an eye toward federal approval of psychedelic medications by the Food and Drug Administration (FDA).

The document says that substances such as psilocybin, LSD and MDMA “show potential in clinical studies for treating depression, post-traumatic stress disorder, anxiety, and substance use disorders,” though it cautions that the evidence base “remains uneven and important methodological limitations persist.”

State Preparation and Legal Tensions

State officials should “consider planning now for the fiscal, legal, and operational implications of potential FDA-approved psychedelic therapies, including any Medicaid coverage obligations,” it says.

They should also work toward “developing oversight frameworks, including credentialing standards, safety protocols, informed consent processes, and complaint mechanisms proactively, before psychedelic therapies are formally made available for state system service recipients,” the SAMHSA report recommends.

Related Stories

Friday

Friday is a San Diego based writer covering cannabis news, culture, and business. Known for sharp analysis and clean reporting, Friday helps readers navigate the industry without the fluff. Every article is built on research, real sources, and a deep commitment to the cannabis community.

Recent Posts

Hall of Flowers Returns To Pier 36 With First Ever Public Programming In New York

The Show Returns To Pier 36 Hall of Flowers returns to Pier 36 for its second New York run on…

2 hours ago

LEEF Brands CEO Says Decades In Mendocino Cultivation Shaped His Interstate Commerce Playbook

From Mendocino Grower to Supply Chain CEO Micah Anderson, CEO of publicly traded LEEF Brands, has spent nearly three decades…

13 hours ago

Houston Chronicle Endorses Prop A As A Stopgap While Texas Marijuana Laws Stay Mired In Confusion

Chronicle Editorial Board Backs Proposition A The Houston Chronicle has endorsed Proposition A, a ballot measure that would require Houston…

16 hours ago

Cannabis Industry Digest For October 18 2026

This week the cannabis industry's hemp debate took center stage, with a former Marijuana Policy Project staffer publicly breaking with…

1 day ago

Cochrane Review Finds No Solid Proof Medical Cannabis Treats Insomnia

What the Review Found A new Cochrane review has concluded that existing evidence is too uncertain to determine whether medical…

1 day ago

Fifteen Suspects Indicted For Smash And Grab Burglaries Targeting Portland Cannabis Shops

Fifteen Indicted in Portland Cannabis Burglary Ring Officials have indicted 15 suspects accused of participating in a Portland, Oregon, burglary…

2 days ago

NUG Magazine is published and distributed by NUG Magazine LLC. Established in 2009,
We have been bringing you the latest and up to date information from the cannabis market.
All contents are for entertainment and educational purposes only and are intended for mature audiences.

Products

Search Nug Magazine!

Advertisement

Instagram @Nugmagazine

[instagram-feed]

About NUG

We are the #1 Source for your Cannabis news and information